Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib

Calithera Biosciences (NASDAQ:CALA) has announced the first patietn has been treated in its Phase 1/2 open-label clinical trial of the...

5 Top Weekly NASDAQ Biotech Stocks: MannKind Leads the Pack

MannKind, Sierra Oncology, Eiger BioPharmaceuticals, Aevi Genomic Medicine and KalVista Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology...

Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839

Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced two new...

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839

Calithera Biosciences (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the...

Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights

Calithera Biosciences (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism...

5 Top NASDAQ Pharma Stocks of Q1 2017

Here's a look at which NASDAQ-listed pharma stocks have seen the biggest gains year-to-date.